Edition:
India

EyePoint Pharmaceuticals Inc (EYPT.OQ)

EYPT.OQ on NASDAQ Stock Exchange Global Market

2.44USD
20 Jul 2018
Change (% chg)

$-0.04 (-1.61%)
Prev Close
$2.48
Open
$2.48
Day's High
$2.65
Day's Low
$2.38
Volume
184,661
Avg. Vol
109,456
52-wk High
$2.87
52-wk Low
$0.93

Latest Key Developments (Source: Significant Developments)

EyePoint Pharmaceuticals Reports Q3 Loss Per Share $0.15
Wednesday, 9 May 2018 

May 8 (Reuters) - EyePoint Pharmaceuticals Inc ::EYEPOINT PHARMACEUTICALS REPORTS FISCAL THIRD QUARTER 2018 RESULTS.Q3 LOSS PER SHARE $0.15.Q3 REVENUE $928,000 VERSUS $590,000.Q3 REVENUE VIEW $723,000 -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.13 -- THOMSON REUTERS I/B/E/S.  Full Article

pSivida announces Acquisition Of Icon Bioscience, financing agreements
Thursday, 29 Mar 2018 

March 28 (Reuters) - pSivida Corp ::PSIVIDA CORP. ANNOUNCES TRANSFORMATIVE ACQUISITION OF ICON BIOSCIENCE INC. AND GROWTH CAPITAL FINANCING WITH ESSEX WOODLANDS HEALTHCARE PARTNERS – COMPANY WILL REBRAND AS EYEPOINT PHARMACEUTICALS, INC..EW HEALTHCARE & THIRD PARTY INVESTOR TO MAKE INVESTMENT IN CO OF UP TO ABOUT $60.5 MILLION .SWK HOLDINGS WILL PROVIDE UP TO $20 MILLION IN DEBT FINANCING.PSIVIDA CORP. WILL REBRAND AND CHANGE ITS NAME TO EYEPOINT PHARMACEUTICALS INC..ENTERED INTO A FINANCIAL AGREEMENT WITH EW HEALTHCARE PARTNERS.EW HEALTHCARE PARTNERS AND A THIRD PARTY INVESTOR WILL MAKE EQUITY INVESTMENTS IN PSIVIDA.WILL USE FUNDS TO FINANCE ICON ACQUISITION AND PREPARE FOR COMMERCIAL LAUNCHES OF DEXYCU.IF APPROVED, PSIVIDA EXPECTS TO LAUNCH DURASERT IN U.S. IN FIRST HALF OF 2019.PSIVIDA PLANS TO LAUNCH DEXYCU IN U.S. IN FIRST HALF OF 2019.EW HEALTHCARE PARTNERS AND A THIRD PARTY INVESTOR WILL MAKE AN EQUITY INVESTMENT IN PSIVIDA FOR UP TO ABOUT $60.5 MILLION.  Full Article

pSivida Submits New Drug Application For Durasert Three-Year Treatment For Posterior Segment Uveitis To The U.S. FDA
Monday, 8 Jan 2018 

Jan 8 (Reuters) - pSivida Corp ::PSIVIDA SUBMITS NEW DRUG APPLICATION (NDA) FOR DURASERT™ THREE-YEAR TREATMENT FOR POSTERIOR SEGMENT UVEITIS TO THE U.S. FDA.PSIVIDA CORP - ‍SUBMITTED NDA TO U.S. FDA FOR DURASERT THREE-YEAR TREATMENT FOR POSTERIOR SEGMENT UVEITIS​.  Full Article

Psivida Granted Waiver By The FDA For New Drug Application Filing Fee
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Psivida Corp ::PSIVIDA GRANTED WAIVER BY THE FDA FOR NEW DRUG APPLICATION FILING FEE.PSIVIDA CORP - ON TRACK TO FILE DURASERT NDA IN EARLY JANUARY.PSIVIDA - FDA GRANTED BUSINESS WAIVER OF PDUFA FEE OF ABOUT $2.4 MILLION FOR NDA FOR CO'S DURASERT 3 YEAR MICROINSERT FOR POSTERIOR SEGMENT UVEITIS.  Full Article

pSivida reports Q1 loss per share of $0.15
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - pSivida Corp ::Q1 loss per share $0.15.Q1 revenue $385,000 versus $277,000.Q1 revenue view $640,000 -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S.  Full Article

Nicox and pSivida enter collaboration agreement to develop sustained release drug for glaucoma patients​
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Nicox SA :Nicox-Co and pSivida enter strategic collaboration agreement to develop sustained release drug to lower intraocular pressure in patients with glaucoma​.Would make additional payments for any incremental development activities for each implant formulation product candidate.Expected payments from Nicox associated with agreement are not considered material to Nicox's financial statements at this time​.Says ‍pSivida will be responsible for initial development activities of ocular insert formulations, for which it will receive undisclosed sums​.  Full Article

Nicox and pSivida enter strategic collaboration agreement
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - NICOX SA ::REG-NICOX AND PSIVIDA ENTER STRATEGIC COLLABORATION AGREEMENT TO DEVELOP SUSTAINED RELEASE DRUG TO LOWER INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA.NEW INTELLECTUAL PROPERTY FROM THE COLLABORATION RELATING TO THE DRUG-DEVICE COMBINATION WILL BE JOINTLY OWNED‍​.PSIVIDA TO BE RESPONSIBLE FOR INITIAL DEVELOPMENT ACTIVITIES OF OCULAR INSERT FORMULATIONS, FOR WHICH IT WILL RECEIVE UNDISCLOSED SUMS BY NICOX‍​.  Full Article

pSivida says primary endpoint met in utilization study of new Medidur inserter with smaller diameter needle
Tuesday, 9 Aug 2016 

pSivida Corp : Psivida corp says primary endpoint met in psivida's utilization study of new medidur inserter with smaller diameter needle .Results of study will form part of planned u.s. Nda and application for eu marketing authorization for medidur for posterior uveitis.  Full Article